249 related articles for article (PubMed ID: 9213613)
1. The position of intellectual property rights in drug discovery and development from natural products.
Boyd MR
J Ethnopharmacol; 1996 Apr; 51(1-3):17-25; discussion 25-7. PubMed ID: 9213613
[TBL] [Abstract][Full Text] [Related]
2. Juridical and sociocultural problems on the definition of a law concerning property, usage and access to genetic resources in Colombia.
Calle R
J Ethnopharmacol; 1996 Apr; 51(1-3):127-42; discussion 142-6. PubMed ID: 9213609
[TBL] [Abstract][Full Text] [Related]
3. Tanzania's policy on biodiversity prospecting and drug discovery programs.
Mahunnah RL; Mshigeni KE
J Ethnopharmacol; 1996 Apr; 51(1-3):221-8. PubMed ID: 9213620
[TBL] [Abstract][Full Text] [Related]
4. Legal issues in sharing the benefits of biodiversity prospecting.
Mays TD; Mazan KD
J Ethnopharmacol; 1996 Apr; 51(1-3):93-102; discussion 102-9. PubMed ID: 9213633
[TBL] [Abstract][Full Text] [Related]
5. Interests and policies of the state of Sarawak, Malaysia regarding intellectual property rights for plant derived drugs.
Chung FJ
J Ethnopharmacol; 1996 Apr; 51(1-3):201-4. PubMed ID: 9213617
[TBL] [Abstract][Full Text] [Related]
6. Medicinal plant genetic resources and international cooperation: the Brazilian perspective.
Elisabetsky E; Costa-Campos L
J Ethnopharmacol; 1996 Apr; 51(1-3):111-9; discussion 119-20. PubMed ID: 9213607
[TBL] [Abstract][Full Text] [Related]
7. The UIC ICBG (University of Illinois at Chicago International Cooperative Biodiversity Group) Memorandum of Agreement: a model of benefit-sharing arrangement in natural products drug discovery and development.
Soejarto DD; Gyllenhaal C; Fong HH; Xuan LT; Hiep NT; Hung NV; Bich TQ; Southavong B; Sydara K; Pezzuto JM
J Nat Prod; 2004 Feb; 67(2):294-9. PubMed ID: 14987071
[TBL] [Abstract][Full Text] [Related]
8. Biological diversity, indigenous knowledge, drug discovery and intellectual property rights: creating reciprocity and maintaining relationships.
King SR; Carlson TJ; Moran K
J Ethnopharmacol; 1996 Apr; 51(1-3):45-57. PubMed ID: 9213630
[TBL] [Abstract][Full Text] [Related]
9. [Intellectual property rights in Costa Rica in the light of the Biodiversity Convention].
Salazar R; Cabrera JA
J Ethnopharmacol; 1996 Apr; 51(1-3):177-93. PubMed ID: 9213615
[TBL] [Abstract][Full Text] [Related]
10. Access to affordable HIV/AIDS drugs: the human rights obligations of multinational pharmaceutical corporations.
Ferreira L
Fordham Law Rev; 2002 Dec; 71(3):1133-79. PubMed ID: 12523370
[No Abstract] [Full Text] [Related]
11. [Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].
Chaves GC; Oliveira MA; Hasenclever L; de Melo LM
Cad Saude Publica; 2007 Feb; 23(2):257-67. PubMed ID: 17221075
[TBL] [Abstract][Full Text] [Related]
12. Pills, patents, and power: state creation of gray markets as a limit on patent rights.
Ghosh S
Fla J Int Law; 2002; 14(2):217-60. PubMed ID: 16526138
[No Abstract] [Full Text] [Related]
13. Intellectual property rights and traditional medicine: policy dilemmas at the interface.
Timmermans K
Soc Sci Med; 2003 Aug; 57(4):745-56. PubMed ID: 12821021
[TBL] [Abstract][Full Text] [Related]
14. Drug patents and intellectual property rights.
Raj GM; Priyadarshini R; Mathaiyan J
Eur J Clin Pharmacol; 2015 Apr; 71(4):403-9. PubMed ID: 25640303
[TBL] [Abstract][Full Text] [Related]
15. Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.
Spectar JM
Houst J Int Law; 2002; 24(2):227-78. PubMed ID: 16189914
[No Abstract] [Full Text] [Related]
16. "Studies on biodiversity of Vietnam and Laos" 1998-2005: examining the impact.
Soejarto DD; Zhang HJ; Fong HH; Tan GT; Ma CY; Gyllenhaal C; Riley MC; Kadushin MR; Franzblau SG; Bich TQ; Cuong NM; Hiep NT; Loc PK; Xuan le T; Hai NV; Hung NV; Chien NQ; Binh le T; Vu BM; Ly HM; Southavong B; Sydara K; Bouamanivong S; Pezzuto JM; Rose WC; Dietzman GR; Miller BE; Thuy TV
J Nat Prod; 2006 Mar; 69(3):473-81. PubMed ID: 16562860
[TBL] [Abstract][Full Text] [Related]
17. [Essential medicines and the TRIPS Agreement: collision between the right to health and intellectual property rights].
Allard Soto R
Salud Colect; 2015 Mar; 11(1):9-21. PubMed ID: 25853827
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceutical patents and some international trade issues: Canada, the United States, and NAFTA.
Tancer RS
Clin Ther; 1993; 15(6):1177-84; discussion 1120. PubMed ID: 8111813
[TBL] [Abstract][Full Text] [Related]
19. Intellectual property. Challenges to India's pharmaceutical patent laws.
Sampat BN; Shadlen KC; Amin TM
Science; 2012 Jul; 337(6093):414-5. PubMed ID: 22767892
[No Abstract] [Full Text] [Related]
20. Patenting bioactive molecules from biodiversity: the Brazilian experience.
Nogueira RC; de Cerqueira HF; Soares MB
Expert Opin Ther Pat; 2010 Feb; 20(2):145-57. PubMed ID: 20099999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
